Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at http://www.roche.com

    All trademarks used or mentioned in this release are legally protected.

    References

    ---------------------------------

    (i) World Health Organization,
       http://www.who.int/cancer/detection/breastcancer/en/

    (ii) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
         Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
         Lyon, 2004. 2004.

    (iii) Harries M, Smith I. The development and clinical use of trastuzumab
          (Herceptin). Endocr Relat Cancer 9: 75-85, 2002.

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
(Date:3/31/2015)... UHC has released the findings of a new study ... cost and quality outcomes to uncover several trends related ... utilization of PPIs—which can account for 30% to 40% ... medical centers, focusing on procedures utilizing orthopedic implants, coronary ... The study, begun in 2013, integrated the pilot test ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 /PRNewswire/ ...  VSCI) today announced the completion of their merger. ... and completion of the all-stock combination creates a ... Beginning on April 1, 2015, Cogentix Medical, Inc. ... CGNT. Cogentix Medical will have its U.S. headquarters ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... Mass., Nov. 16, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: ... and development of drugs for the treatment of human viral ... offering of 9,393,416 shares of its common stock at a ... shares are being sold by Idenix. The offering is expected ...
... YORK, Nov. 16, 2011 Reportlinker.com ... report is available in its catalogue: ... Cancer, Angiogenesis and Peptides ... This triple analysis focuses on cancer ...
Cached Medicine Technology:Idenix Pharmaceuticals Prices Public Offering of Common Stock 2Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 2Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 3Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 4Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 5
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... (ADS) is offering advice for buying from a ... Dealers Association (NMEDA) is a nonprofit organization that ... in the manufacturing and installation of mobility equipment. ... in the industry that consistently adhere to the ...
(Date:3/31/2015)... Calling all runners, walkers and everyone who ... diseases! The first annual “Lyme Walk & Run” will be ... CT. The event, hosted by Lyme Research Alliance (LRA) ... to support research and education about Lyme and other tick-borne ... and abilities, will feature 5K and 10K runs and one-mile ...
(Date:3/31/2015)... Hollywood, Florida (PRWEB) March 31, 2015 ... that activities like basketball, rock climbing, and cycling are ... called Adaptive Sports at Memorial Rehabilitation Institute aims to ... the Memorial Healthcare System, will host an Adaptive Sports ... p.m.) at Memorial Regional Hospital South in Hollywood. ...
(Date:3/31/2015)... NB (PRWEB) March 31, 2015 Indosoft, developer ... of Asterisk 1.4 support in development of their 5.x line. ... for Asterisk has been deployed around the world for more ... Asterisk 1.4 as a telephony platform, Q-Suite can fully embrace ... providing quality call center software on Asterisk for more than ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2
... person with a disability, MINNEAPOLIS, Nov. 6 ... recipient of the 2008 Judd Jacobson Memorial Award.,Established in ... pursuit or achievement in a business entrepreneurial,endeavor by a ... Kusiak, 48, is a paraplegic as the result of ...
... 2008 A major issue in the development of ... damaged tissues. In a review of the issue published ... regeneration in humans from the body,s own tissues by ... answered before the process can reach clinical status. , ...
... ResMed Inc. (NYSE: RMD ),today announced record ... 2008. Revenue for the quarter was $217.9 million, a ... the current,quarter, income from operations was $36.6 million and ... 16%, respectively, compared to the quarter,ended September 30, 2007. ...
... mass maintenance, study finds , , THURSDAY, Nov. 6 (HealthDay ... bones, which can lead to a decrease in bone ... In previous research, the study authors, from Loyola University ... rats large amounts of alcohol caused significant decreases in ...
... 915, BALTIMORE, Nov. 6 The following ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ), WHEN: Tuesday, ... outside the Baltimore Marriott Waterfront Hotel, 700,Aliceanna St., ... Maryland Right to Life, Defend Life and the,Catholic ...
... the Innovative Program Targeting Adolescents, PHILADELPHIA, ... (AHIP) will recognize Independence Blue Cross (IBC) ... adolescents to get the,important, recommended immunizations they ... against dangerous, infectious diseases like,meningitis and HPV, ...
Cached Medicine News:Health News:Wisconsin Farmer Ronald Kusiak Honored With 2008 Jacobson Memorial Award 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 7Health News:Alcohol Abuse Can Damage Bones 2Health News:Coalition Asks Bishops to Take Politicians to Task 2Health News:Independence Blue Cross Honored for Immunization Program 2Health News:Independence Blue Cross Honored for Immunization Program 3
The upper body blanket is typically used for abdominal or lower body procedures. The upper body blankets warms the upper torso and arms. A clear drape is included to cover and warm the intubated pati...
Soft yet durable, these single-patient use pads are designed to have the quality look of reusable pads but provide the hygienic advantages of disposability....
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Medicine Products: